The effect of this therapy has not been sufficiently evaluated in patients with TNBC, but the better clinical response is associated with increased stromal TILs (sTILs) and intratumoral TILs (iTILs), in addition to increased pretherapeutic PD-L1 expression on tumor cells. This evidence concerns the gene CD274 and neoplasm.